Fibrocell Science Inc (FCSC) 2004年年度报告「NASDAQ」.pdf

1、Use these links to rapidly review the documentTABLE OF CONTENTS Index to Consolidated Financial StatementsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KAnnual Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934For the fiscal year ended December

2、31,2004ORoTransition Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934Isolagen,Inc.(Exact name of registrant as specified in its Charter.)Delaware(State or other jurisdictionof incorporation)001-31564(Commission File Number)87-0458888(I.R.S.EmployerIdentification No.)102 P

3、ickering WayExton,Pennsylvania 19341(Address of principal executive offices,including zip code)(484)875-3099(Issuers telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Name of Each Exchange on which RegisteredCommon Stock,$.001 par valu

4、e American Stock Exchange Indicate by check mark whether the registrant:(1)filed all reports required to be filed by Section 13 or 15(d)of the Exchange Act during thepreceding 12 months(or for any shorter period that the registrant was required to file such reports),and(2)has been subject to such fi

5、lingrequirements for the past 90 days.Yes No o Indicate by check mark if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-K contained in this form,and nodisclosure will be contained,to the best of registrants knowledge,in definitive proxy or information statements

6、incorporated by reference in Part IIIof this Form 10-K or any amendment to this Form 10-K.o Indicate by check mark whether the registrant is an accelerated filer(as defined in the Exchange Act Rule 12b-2)Yes No o As of June 30,2004,the aggregate market value of the issuers common stock held by non-a